Share this article Share this article ResearchAndMarkets.com's offering. Cancer Screening Suffers a Pandemic Induced Setback The global market for Colonoscopy Devices is expected to slump by -8.2% in the year 2020, before recovering to reach a revised US$1.9 billion by the year 2027, trailing a 3.8% CAGR over the analysis period2020 to 2027. Six months into the pandemic, the COVID-19 crisis continues to evolve & shows no signs of receding. Endoscopy the mainstay for the diagnosis & management of colorectal cancer is coming under pressure as COVID-19 continues to spread. All non-urgent procedures are being either rescheduled or replaced by alternative biomarkers. Even as hospitals reopen for routine care, shortage of P.P.E & greater attention to endoscopic room hygiene & disinfection are impacting patient throughput rates. The low levels of screening raises the risk of missed, delayed diagnosis & higher mortality. In short, the pandemic is having a negative impact on the economy and healthcare. The risk of contracting the infection in healthcare settings is discouraging people from screening and treatment for various conditions including cancer. Colorectal cancer screening has declined drastically in the US, risking up to 18,000 delayed or missed diagnoses between March and June.